Skip to main content
Equibles
NIKA logo

NIKA · Nika Pharmaceuticals, Inc · Executive Compensation

Track NIKA — free

Use NIKA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NIKA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.41 At close · Sep 7
Rebalance outlook locked
Going-concern doubt — flagged Aug 10, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.”
View the 10-Q filed Aug 10, 2026
Market Cap
$431.19M
Shares
1.05B
Volume · Sep 7 2500 Avg daily vol (10 sessions) 1247

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

No Compensation Data

No Summary Compensation Table has been imported from this company's proxy statements yet.

Leadership

Key facts CIK 1145604 Visit website Investor relations